COVID‐19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS‐CoV‐2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Lisa Domegan, Noémie Sève et al.|Influenza and Other Respiratory Viruses|2025Cited by 10
COVID-19 Vaccine Effectiveness against Medically Attended Symptomatic SARS-CoV-2 Infection among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care NetworkCharlotte Lanièce Delaunay, Esther Kissling, Nuno Verdasca et al.|SSRN Electronic Journal|2025Cited by 0